Nivalis Therapeutics Inc (NVLS)

2.35
NASDAQ : Health Care
Prev Close 2.35
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.00 / 9.35
Avg Volume 140.30K
Exchange NASDAQ
Shares Outstanding 15.66M
Market Cap 36.64M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Nivalis Therapeutics, Inc. And Alpine Immune Sciences, Inc. Agree To Combine

Nivalis Therapeutics, Inc. (NASDAQ: NVLS) and Alpine Immune Sciences, Inc.

Nivalis Therapeutics Reports Fourth Quarter And Full-Year 2016 Financial Results

Review of Strategic Alternatives Progressing as Operations Streamlined

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Nivalis Therapeutics Announces Results From Phase 2 Clinical Trial Of Cavosonstat For Treatment Of Cystic Fibrosis

Nivalis Therapeutics Announces Results From Phase 2 Clinical Trial Of Cavosonstat For Treatment Of Cystic Fibrosis

Company to Host Conference Call Today, November 28, at 5:00 p.m. EST

Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

Completion of Enrollment in Phase 2 Study of Cavosonstat for Treatment of Cystic Fibrosis Achieved During the Quarter

7 Stocks Under $10 Making Big Up Moves

7 Stocks Under $10 Making Big Up Moves

Here's a technical look at how to trade several under-$10 stocks that were making big moves to the upside recently.

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone In Phase 2 Clinical Trial In Cystic Fibrosis

Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone In Phase 2 Clinical Trial In Cystic Fibrosis

Company on track to report results from the study in fourth quarter this year

Need For Patient-Centric Clinical Trials Fuels Adoption Of Greenphire's ClinCard Solution

Need For Patient-Centric Clinical Trials Fuels Adoption Of Greenphire's ClinCard Solution

Industry-leading patient reimbursement solution reaches milestone of 3 million transactions, totaling more than $200 million in patient reimbursements worldwide